---
layout: talk_reveal4
title: SARS-CoV-2 evolution, seasonality and immunity
venue: COVID DivDir
author: Trevor Bedford
widescreen: true
draft: true
---

<!-- ~15 min talk length to allow for plenty of questions -->

<!-- Color ramp: [#5097BA", "#60AA9E", "#75B681", "#8EBC66", "#AABD52", "#C4B945", "#D9AD3D", "#E59637", "#E67030", "#DF4327"] -->

<!--

Topics:
1. Evolution overview and continued spike mutation accumulation in 2022
2. BA.2.75.2 and other emerging variants
3. Seasonality and near-term circulation patterns
4. OAS, vaccination and fate mapping manuscript

1. Evolution overview and continued spike mutation accumulation in 2022
 - Emphasize continued accumulation of spike mutations within Omicron
 - Mention potential for new "Omicron-like" emergence
2. BA.2.75.2 and other emerging variants
 - Reference BA.4/BA.5 figures from May 17 and ability to project epidemics
 - Describe BA.2.75 and BA.2.75.2
 - Discuss other emerging variants
3. Seasonality and near-term circulation patterns
 - Describe seasonality-gating vs immuninity-gating
 - Discuss potential for seasonality driven epidemic
4. OAS, vaccination and fate mapping manuscript
 - Briefly outline main results of paper
 - Emphasize importance of not just focusing on titers as endpoint for vaccine decision making
 - Specifically emphasize rationale for monovalent over bivalent vaccine
-->

<section data-transition="fade" data-background="#000">
	<h2 class="title">{{ page.title }}</h2>
	<br>&nbsp;<br>
	<p class="title">
	Trevor Bedford (@trvrb)
	<br>
	Fred Hutchinson Cancer Center / Howard Hughes Medical Institute
	<br>
	{{ page.date | date: "%-d %b %Y" }}
	<br>
	{{ page.venue }}
</section>

<section class="left-align">
	<h3>1. Evolution overview</h3>
	<h3>2. Emerging variants</h3>
	<h3>3. Seasonality and near-term circulation</h3>
	<h3>4. Antigenic imprinting and vaccination</h3>
</section>

<!-- Evolution overview -->

<section data-transition="fade" data-background="#5097BA">
	<h1 class="title">Evolution overview</h1>
</section>

<section>
	<h3>Rapid displacement of existing diversity by emerging variants</h3>
	<img class="stretch" data-src="/images/talks/ncov_tree_freq_2022_09_17.png">
	<div class="citation">
		<a href="https://nextstrain.org/ncov/gisaid/global/all-time/2022-09-17">nextstrain.org</a>
	</div>
</section>

<section>
	<h3>S1 evolved at a rate of 13 amino acid changes per year since pandemic start</h3>
 	<img class="stretch" data-src="/images/talks/ncov_mutation_rate_spike_clock_2022_09_17.png">
</section>

<section>
	<h3>Continued rapid accumulation from BA.2 onwards with 7 amino acid changes per year</h3>
 	<img class="stretch" data-src="/images/talks/ncov_mutation_rate_spike_clock_since_ba2_2022_09_17.png">
</section>

<!-- Emerging variants -->

<section data-transition="fade" data-background="#60AA9E">
	<h1 class="title">Emerging variants</h1>
</section>

<section>
 <h3>May 17: fitness advantage of BA.4/BA.5 clear even though rare</h3>
 <img class="stretch" data-src="/images/talks/ncov_variants_rt_us_frequencies_logit_2022_05_17.png">
</section>

<section>
 <h3>BA.2.75 and sublineage BA.2.75.2 emerging from India</h3>
 <img class="stretch" data-src="/images/talks/ncov_variants_ba275_tree_map.png">
 <div class="citation">
	 <a href="https://nextstrain.org/groups/blab/ncov/ba275-in-india">nextstrain.org</a>
 </div>
</section>

<section>
	<h3>BA.2.75(.2) shows consistent selective advantage in India and US</h3>
	<img class="stretch" src="/images/talks/ncov_variants_ba275_logit_frequencies_2022_09_17.png">
</section>

<section>
	<h3>BA.2.75.2 has current Rt in the US of ~1.4</h3>
	<img class="stretch" src="/images/talks/ncov_variants_ba275_rt_log_cases_2022_09_17.png">
	<div class="citation">
		Model from <a href="/papers/figgins-rt-from-frequency-dynamics/">Figgins and Bedford. 2022. medRxiv.</a>
	</div>
</section>

<section>
	<h3>However, multiple low frequency Pango lineages that may compete with BA.2.75.2</h3>
	<img class="stretch" src="/images/talks/ncov_variants_emerging_variants_cov-spectrum_2022_09_18.png">
	<div class="citation">
		<a href="https://cov-spectrum.org/collections/24">CoV-Spectrum.org</a>
	</div>
</section>

<!-- Seasonality and near-term circulation -->

<section data-transition="fade" data-background="#75B681">
	<h1 class="title">Seasonality and near-term circulation</h1>
</section>

<section>
	<h3>Seasonality clearly evidence in 2020-2021 winter epidemic</h3>
	<p>Rt analysis suggests a ~30% transmission advantage going from Aug 2020 to Nov 2020</p>
	<img class="stretch" src="/images/talks/ncov_rt_across_states_2020_11_13.jpg">
	<div class="citation">
		Data from rt.live
	</div>
</section>

<section>
	<h3>Seasonality alone unlikely to drive BA.5 epidemic, but seasonality + novel variants will likely drive epidemics</h3>
	<img class="stretch" src="/images/talks/ncov_variants_rt_us_log_cases_2022_09_17.png">
	<div class="citation">
		Model from <a href="/papers/figgins-rt-from-frequency-dynamics/">Figgins and Bedford. 2022. medRxiv.</a>
	</div>
</section>

<section>
	<h3>Generally, we expect faster antigenic drift to smooth summer vs winter circulation</h3>
	<img class="stretch" src="/images/talks/ncov_seasonality_sirs_model_varying_waning.png">
	<div class="citation">
		<a href="https://twitter.com/trvrb/status/1554890573781168128">@trvrb</a>
	</div>
</section>

<section class="left-align">
	<h3>Heading into fall, we very roughly have:</h3>
	<p>
	<ul>
		<li>
			30% of the population with BA.2, BA.4, BA.5 in Mar 1 to Sep 15 (16.3M confirmed cases
			and 6x under-reporting)
		</li>
		<li>
			40% of the population with BA.1 infection in Jan/Feb (24.1M confirmed cases and
			5x under-reporting)
		</li>
		<li>
			30% of the population vaccinated, boosted or with pre-Omicron infection
		</li>
	</ul>
	</p>
</section>

<!-- Antigenic imprinting and vaccination -->

<section data-transition="fade" data-background="#8EBC66">
	<h1 class="title">Antigenic imprinting and vaccination</h1>
</section>

<section class="left-align">
	<h3>Schiepers, Victora and colleagues: Molecular fate-mapping of serum antibodies reveals the effects of antigenic imprinting on repeated immunization</h3>
	<p><i>Igk</i><sup>Tag</sup> mice switch from FLAG-tag to Strep-tag via Cre recombinase</p>
	<p>Cre expressed germinal centers after tamoxifen exposure</p>
	<img class="stretch" src="/images/talks/oas_fate_mapping_system_schiepers.png">
	<div class="citation">
		<a href="https://www.biorxiv.org/content/10.1101/2022.08.29.505743v2">Schiepers et al. 2022. bioRxiv.</a>
	</div>
</section>

<section>
	<h3>Boosts of same antigen recall Strep+ cells from primary immunization</h3>
	<img class="stretch" src="/images/talks/oas_fate_mapping_tnp_klh_schiepers.png">
	<div class="citation">
		<a href="https://www.biorxiv.org/content/10.1101/2022.08.29.505743v2">Schiepers et al. 2022. bioRxiv.</a>
	</div>
</section>

<section>
	<h3>Boosting with wild type WH1 vs Omicron BA.1</h3>
	<img class="stretch" src="/images/talks/oas_fate_mapping_design_schiepers.png">
	<div class="citation">
		<a href="https://www.biorxiv.org/content/10.1101/2022.08.29.505743v2">Schiepers et al. 2022. bioRxiv.</a>
	</div>
</section>

<section>
	<h3>Boosting with wild type WH1 vs Omicron BA.1</h3>
	<img class="stretch" src="/images/talks/oas_fate_mapping_titers_schiepers.png">
	<div class="citation">
		<a href="https://www.biorxiv.org/content/10.1101/2022.08.29.505743v2">Schiepers et al. 2022. bioRxiv.</a>
	</div>
</section>

<section>
	<h3>Newly elicited FLAG+ antibodies are more potent</h3>
	<img class="stretch" src="/images/talks/oas_fate_mapping_potency_schiepers.png">
	<div class="citation">
		<a href="https://www.biorxiv.org/content/10.1101/2022.08.29.505743v2">Schiepers et al. 2022. bioRxiv.</a>
	</div>
</section>

<section class="left-align">
	<h3>
		I would conclude that only paying attention to neutralizing titers is the wrong strategy. For example,
		monovalent BA.4/BA.5 may produce similar titers to bivalent prototype + BA.4/BA.5, but monovalent should
		better engender a novel response that creates an enduring population of more potent antibodies.
	</h3>
</section>

<section>
	<h3>Acknowledgements</h3>

	<p class="even-smaller">
		<b>SARS-CoV-2 genomic epi</b>: Data producers from all over the world, GISAID and the Nextstrain team
	</p>

	<p class="tiny"><b>Bedford Lab</b>:
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/john-huddleston.jpg"> John Huddleston,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/james-hadfield.jpg"> James Hadfield,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/katie-kistler.jpg"> Katie Kistler,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/maya-lewinsohn.jpg"> Maya Lewinsohn,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/thomas-sibley.jpg"> Thomas Sibley,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/jover-lee.jpg"> Jover Lee,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/cassia-wagner.jpg"> Cassia Wagner,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/miguel-paredes.jpg"> Miguel Paredes,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/nicola-mueller.jpg"> Nicola MÃ¼ller,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/marlin-figgins.jpg"> Marlin Figgins,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/denisse-sequeira.jpg"> Denisse Sequeira,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/victor-lin.jpg"> Victor Lin,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/jennifer-chang.jpg"> Jennifer Chang,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/eslam-abousamra.jpg"> Jennifer Chang,</span> &hairsp;
		<span class="nobreak"><img width=35 class="img-avatar" src="/images/team/donna-modrell.jpg"> Donna Modrell</span>
	</p>

	<div class="pull-right" style="vertical-align: bottom; display: table-cell;">
		<img width="11%" data-src="/images/talks/logo_fred_hutch_vertical.png">
		&nbsp; &nbsp;
		<img width="8%" data-src="/images/talks/logo_pew.png">
		&nbsp; &nbsp;
		<img width="14%" data-src="/images/talks/logo_bmgf.png">
		&nbsp; &nbsp;
		<img width="12%" data-src="/images/talks/logo_gates_ventures.png">
		&nbsp; &nbsp;
		<img width="11%" data-src="/images/talks/logo_wellcome_trust.jpg">
		&nbsp; &nbsp;
		<img width="7%" data-src="/images/talks/logo_nih.jpg">
		&nbsp; &nbsp;
		<img width="8%" data-src="/images/talks/logo_hhmi.jpg">
	</div>
</section>
